Most Read Articles
Naomi Rodrig, 27 Apr 2016

LUX-Lung 7, a global phase IIb, randomized, open-label trial, demonstrated significant improvements in progression-free survival (PFS), time to treatment failure (TTF) and objective response rate (ORR) with afatinib vs gefitinib as first-line treatment for patients with advanced, EGFR-positive non-small-cell lung cancer (NSCLC). [ELCC 2016, abstract 140PD]

Naomi Rodrig, 28 Apr 2016
A combination of live-bacterium immunotherapy and standard chemotherapy is safe and effective in patients with malignant pleural mesothelioma (MPM), providing a response rate of nearly 60 percent, according to a recent phase Ib trial. [ELCC 2016, abstract 208O_PR]
Pearl Toh, 13 May 2017
Short-term use of oral corticosteroids was associated with increased risks of adverse events such as fracture, sepsis, and venous thromboembolism (VTE), a large US cohort study showed.
Naomi Rodrig, 03 May 2016
Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.

The Role of Modern Second-generation Antihistamines in Allergic Rhinitis

25 Jul 2017
Allergic rhinitis (AR) is a common global health problem that poses a significant impact on the quality of life and productivity of affected patients. At the Ear, Nose and Throat (ENT) Summit 2017 held recently at  Hilton Sentral, Kuala Lumpur, Malaysia, Associate Professor Marysia P Tiongco-Recto was invited by A. Menarini to deliver a lecture on the potential of modern second-generation antihistamines, particularly bilastine (Bilaxten®) in the management of AR.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 27 Apr 2016

LUX-Lung 7, a global phase IIb, randomized, open-label trial, demonstrated significant improvements in progression-free survival (PFS), time to treatment failure (TTF) and objective response rate (ORR) with afatinib vs gefitinib as first-line treatment for patients with advanced, EGFR-positive non-small-cell lung cancer (NSCLC). [ELCC 2016, abstract 140PD]

Naomi Rodrig, 28 Apr 2016
A combination of live-bacterium immunotherapy and standard chemotherapy is safe and effective in patients with malignant pleural mesothelioma (MPM), providing a response rate of nearly 60 percent, according to a recent phase Ib trial. [ELCC 2016, abstract 208O_PR]
Pearl Toh, 13 May 2017
Short-term use of oral corticosteroids was associated with increased risks of adverse events such as fracture, sepsis, and venous thromboembolism (VTE), a large US cohort study showed.
Naomi Rodrig, 03 May 2016
Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.